Ibio Stock Price, News & Analysis

iBio announced a breakthrough in bispecific immuno-oncology therapies during a presentation at Carterra's symposium. The Company unveiled a panel of CD3 T-cell binding antibodies, poised to advance T-cell-redirecting bispecific antibodies. These antibodies aim to enhance the immune response against tumors by binding to both T cells and tumor-specific antigens. iBio utilized its patented epitope steering technology and AI-based antibody optimizer to overcome challenges like severe toxicities and lack of cross-reactivity with non-human primates. CEO Martin Brenner highlighted the addition of these antibodies as a valuable asset for enhancing treatment efficacy and safety in future pipeline programs.

iBio, a company specializing in precision antibody immunotherapies, has advanced its anti-CCR8 antibody program into preclinical in vivo testing. This program targets T-regulatory cells, which are pivotal in cancer immunosuppression. The anti-CCR8 antibody aims to selectively deplete Tregs, enhancing the immune system's ability to combat tumors while minimizing potential adverse effects. The development follows the success of iBio’s existing program, IBIO-101, an anti-CD25 antibody. iBio highlights its patented AI epitope steering platform as key to discovering high-value GPCR targets, indicating a promising future for antibody-based therapies.

iBio has announced its latest immune-oncology program targeting MUC16, a protein overexpressed in various solid tumors, including ovarian and pancreatic cancers. Utilizing its patented epitope steering AI platform, iBio's new monoclonal antibodies aim to bind to an unmodifiable region of MUC16, enhancing the effectiveness of cancer treatment by circumventing tumor evasion mechanisms. This addition expands iBio's immuno-oncology portfolio, which already includes programs targeting other cancer-specific proteins. The company emphasizes its commitment to advancing innovative treatments in the biopharmaceutical space.

iBio Inc. (NYSEA:IBIO) announced the issuance of U.S. Patent No. 11,545,238, which covers a machine learning model for designing engineered peptides aimed at improving therapeutic antibody precision. This patent reinforces iBio's leadership in AI-driven drug discovery and strengthens its competitive position in the biotech sector. The RubrYc Discovery Engine is highlighted as a key innovation, facilitating faster identification of effective molecules for challenging drug targets, particularly in hard-to-treat cancers.

iBio, Inc. (NYSEA: IBIO) has completed its public offering of 3,365,385 shares, along with Series A and Series B warrants, at a price of $1.04 each. The offering, partially exercised by underwriters, raised approximately $3.5 million in gross proceeds. Funds will primarily support operating costs, R&D, and general corporate needs. The Company aims to enhance its capabilities in developing new antibody treatments targeting challenging cancers and diseases. The offering was conducted under an SEC shelf registration statement effective since December 2020.

iBio, Inc. (NYSEA: IBIO) announced the pricing of an underwritten public offering of 3,365,385 shares at $1.04 each, with Series A and B warrants included. The offering aims to raise approximately $3.5 million for operating costs, particularly for research, development, and general corporate expenses, including employee payments. The closing is anticipated on or about December 9, 2022. Additionally, the underwriter has a 30-day option to purchase extra shares and warrants. This follows the company's effective shelf registration statement filed with the SEC.

iBio announced plans to conduct an underwritten public offering of common stock and Series A and B warrants, with a potential 30-day underwriter option for additional shares. The proceeds are aimed primarily at operating costs, including research and development and general corporate purposes. The offering, which is subject to market conditions, is associated with a shelf registration statement previously filed. H.C. Wainwright & Co. leads the offering management. iBio aims to strengthen its financial position while focusing on antibody development.

iBio, Inc. (NYSE: IBIO) announced that its Chief Scientific Officer, Martin Brenner, will participate in a virtual fireside chat at the JMP Securities Hematology and Oncology Summit on December 7, 2022, at 1:20 p.m. Eastern Time. The event will be broadcast live and archived on the company's website under the 'News & Events' section. iBio specializes in developing next-generation biopharmaceuticals utilizing computational biology to enhance antibody therapies for difficult-to-treat cancers and diseases.